RE:RE:RE:RE:Would someone pay $ 2B for DIMI?I challenged your logic and now you are upset about it? Don't cry, your margin interest isn't due for a couple of weeks. I hope DIMI/SAMI is worth $2 bil but now to you we are worth $1 to $1.5 bil but you gaslit the value up to $2 bil...quite a haircut. It is dishonest to imply DaVi would pay the same for less and somehow now less is worth more.
mercedesman wrote: PezDalatoYou wrote: There is one big difference. The $2 bil that Fresenius paid for NxStage was for the entire company, at least that's how I read their NR. I'm assuming this would include IP, manufacturing facilities, sales force, etc. Why wouldn't DaVi just buy out Infomed itself? The Infomed NA rights can't be worth $2 bil using NxStage as a comparator. And what protection would Spectral have in the event of an Infomed buyout scenario? Would we be left holding our empty marble bags?
Spectral wouuld have signed a Distribution Agreement that protects its NA Rights in the event of a change in control by Infomed. Assignment clause.
Not sure DaVita wants worldwide Rights or would just prefer focus on the most lucrative US market
Doesn't always make sense to acquire manufacturing capabilites. PMX buyer aren't likely to buy Toray's factories. Most distributors prefer to stick to their knitting.
While NA is not the whole world, factor in worldwide rights to Hemoperfusion using DIMI or SAMI (unless those are "royaltied" away). Plus what premium should be factored into a deal for "disrputive" technology that leads to much much higher market acceptance/penetration? (ie. reduces barriers to adoption)
Even doing the math using $ 1B or $ 1.5B - it's still a substantial asset
Why do SH players always insert FUD, and talk down our asset ? Especially in relation to share value ?
I have a theory....no one wants to jinx any ongoing & complex negotiations.
vs a faction that wants the SP to more fairly reflect the potential.